Scholarlink

Purpose of Review <p>Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating, chronic bladder disorder. Because its etiology remains unclear, no curative treatments are currently available, impairing the quality of life. This review provides an overview of the current understanding of the etiologies of IC/BPS subtypes and evaluates emerging treatment strategies for each subtype.</p> Recent Findings <p>IC/BPS is comprised of two distinct subtypes with different pathogenic mechanisms: Hunner lesion disease (HLD) and BPS. HLD is a distinct inflammatory disease subtype of IC/BPS, characterized clinically by the presence of a Hunner lesion and histologically by urothelial denudation and B-cell abnormality. Meanwhile BPS, which lacks a Hunner lesion, is a symptom syndrome complex consisting of multifactorial phenotypes. Recent improvements in understanding of the pathophysiologies of IC/BPS have led to the development of subtype-directed treatment strategies.</p> Summary <p>The broad spectrum of etiology has been a burden for the treatment of IC/BPS and breaking down the subtypes of IC/BPS will lead us to identify novel therapeutic treatments.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Current Perspectives on the Etiology and Emerging Treatments of Interstitial Cystitis/Bladder Pain Syndrome: A Review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月7日

查看全文
  • Tetsuichi Saito,
  • Yoshiyuki Akiyama

摘要

Purpose of Review

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating, chronic bladder disorder. Because its etiology remains unclear, no curative treatments are currently available, impairing the quality of life. This review provides an overview of the current understanding of the etiologies of IC/BPS subtypes and evaluates emerging treatment strategies for each subtype.

Recent Findings

IC/BPS is comprised of two distinct subtypes with different pathogenic mechanisms: Hunner lesion disease (HLD) and BPS. HLD is a distinct inflammatory disease subtype of IC/BPS, characterized clinically by the presence of a Hunner lesion and histologically by urothelial denudation and B-cell abnormality. Meanwhile BPS, which lacks a Hunner lesion, is a symptom syndrome complex consisting of multifactorial phenotypes. Recent improvements in understanding of the pathophysiologies of IC/BPS have led to the development of subtype-directed treatment strategies.

Summary

The broad spectrum of etiology has been a burden for the treatment of IC/BPS and breaking down the subtypes of IC/BPS will lead us to identify novel therapeutic treatments.